U.S. senators on Friday called for Medicare to offer broad coverage of Alzheimer’s treatments approved by the Food and Drug Administration, warning that current restrictions cost patients precio...
Tag: Alzheimers
Biogen Stock Slumps As Pressure Points Likely To Limit 2023 Alzheimer’s Sales
Biogen (BIIB) stock was hamstrung Wednesday on a mixed 2023 outlook that assumes expenses for new Alzheimer’s treatment will outpace its sales. X Despite beating fourth-quarter expectations, Bio...
Lilly’s Alzheimer’s drug setback is ‘not a thesis-breaker’
Eli Lilly & Co (NYSE: LLY) ended slightly down on Friday after the U.S. FDA rejected its request of accelerated approval for Donanemab – its Alzheimer’s drug. Why did the FDA reject its applicatio...
AN NFT COLLECTION OF SIR GEOFF HURST’S MEMORIES OF THE 1966 WORLD CUP GO TO AUCTION TO SUPPORT ALZHEIMER’S CHARITIES
Sir Geoff Hurst, one of the last living English footballers who retains vivid memories of the historic 1966 World Cup Final, has digitally preserved his recollections from the famous victory against W...
Eli Lilly CEO on guidance cut, potential obesity drug, Alzheimer’s study
Eli Lilly (LLY) CEO David Ricks on Tuesday expressed optimism around the drugmaker’s innovation pipeline Tuesday, a stance we share despite the Club holding’s cluttered quarterly report is...
Biogen Stock Flies On Upgrade; Why Alzheimer’s Is A $7 Billion Opportunity
Biogen (BIIB) could easily take on Roche (RHHBY) and Eli Lilly (LLY) in Alzheimer’s treatment, an analyst said Thursday as he updated Biogen stock. X In response, Biogen stock surged 6.4% to 269...
An Alzheimer’s Drug’s Big Surprise: What It Means
Until this past week, there seemed to be no answers to the Alzheimer’s puzzle. The leading theory of the disease, that it was caused by a buildup of beta amyloid plaque in the brain, had been disprove...
Biogen Stock Explodes Higher After Alzheimer’s Drug Succeeds In Final-Phase Test
Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer’s plays with it — after its experimental treatment succeeded in a final-phase test. X The results are sorely needed fo...
Biogen stock explodes higher after potential ‘mega blockbuster’ Alzheimer’s drug study
Biogen stock (BIIB) is booming amid as Wall Street speculates about a potential profit boom after a promising study detailed the company’s new Alzheimer’s drug in partnership with Japan’s ...
its Alzheimer’s drug could be ‘biggest drug in history’
Shares of Eli Lilly & Co (NYSE: LLY) are in the red this morning after the pharmaceutical giant reported weaker-than-expected results for its fiscal second quarter. Key takeaways from Eli Lilly Q2...
Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug Aduhelm
Topline Biogen CEO Michel Vounatsos will step down as the company continues to cut about $1 billion in costs annually, Biogen said Tuesday, after Medicare limited coverage for its Alzheimer’s drug, Ad...
Inspire Napa Valley 2022 To Benefit Alzheimer’s Association, April 29-May 1
Kerrin Laz, winemaker and founder of K. LAZ Wine Collection, launched Inspire Napa Valley in 2017 as someone directly impacted by the devastation of Alzheimer’s Disease — her beloved mother was diagno...
Biogen Stock: Will The $8 Billion Opportunity Materialize For Alzheimer’s Drugs?
Biogen stock popped Thursday after an analyst suggested the biotech company could reap $8 billion in sales of its Alzheimer’s treatments — assuming everything lines up properly. X But hours late...
Biogen’s stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer’s drug in the fourth quarter
An earlier version of this report had the wrong consensus and revenue numbers. It has been corrected. Shares of Biogen Inc. BIIB, -1.92% were down 3.7% in premarket trading on Thursday after the compa...
Medicare Seeks To Limit Coverage For Controversial Alzheimer’s Drug Aduhelm
Topline The Centers for Medicare and Medicaid Services proposed limiting coverage for Alzheimer’s drug Aduhelm to patients participating in clinical trials Tuesday, after many medical experts claimed ...
Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success
Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...
Why Biogen’s Alzheimer’s drug Aduhelm is so controversial
The U.S. Food and Drug Administration’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands o...
The Scandal Of Alzheimer’s
Why is there no cure for Alzheimer’s—or why aren’t there medications that can at least substantially slow or meaningfully ameliorate the disease? It afflicts more than 6 million Americans, with that n...